The use of pelvic radiation in stage II rectal cancer

A population-based analysis

Isabella Kuo, Jan H. Wong, Sharmila Roy-Chowdhury, Sharon S. Lum, John W. Morgan, Kevork Kazanjian

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

National Institutes of Health (NIH) guidelines recommend the use of pelvic radiation in T3N0 rectal cancer. We sought to determine the rate of compliance with NIH radiation guidelines for patients with T3N0 rectal cancer. We performed a retrospective cohort study of T3N0 rectal cancer diagnosed between January 1, 1994, and December 31, 2003, in Region 5 of the California Cancer Registry (R5 CCR). Three hundred twenty-nine patients with T3N0 rectal cancer were identified. The mean age of the study population was 68 years (range, 28 to 93 years). Only 54.1 per cent of patients with T3N0 cancer received pelvic radiation. There was no difference in gender (P = 0.13) or the number of nodes examined (P = 0.19) between patients who had treatment with pelvic radiation and those who did not. However, patients receiving radiation were significantly younger (mean 64 years with radiation therapy [XRT] vs 72 years without XRT, P <0.001) and significantly more likely to be treated with systemic chemotherapy (75% with XRT vs 8.6% without XRT, P <0.001). Significant numbers of patients with T3N0 rectal cancer are not receiving pelvic radiation in R5 CRR. NIH guidelines are not being translated into clinical practice. The reasons for this warrant continued investigation.

Original languageEnglish (US)
Pages (from-to)1092-1095
Number of pages4
JournalAmerican Surgeon
Volume76
Issue number10
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Rectal Neoplasms
Radiation
National Institutes of Health (U.S.)
Population
Guidelines
Pelvic Neoplasms
Registries
Cohort Studies
Radiotherapy
Retrospective Studies
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Kuo, I., Wong, J. H., Roy-Chowdhury, S., Lum, S. S., Morgan, J. W., & Kazanjian, K. (2010). The use of pelvic radiation in stage II rectal cancer: A population-based analysis. American Surgeon, 76(10), 1092-1095.

The use of pelvic radiation in stage II rectal cancer : A population-based analysis. / Kuo, Isabella; Wong, Jan H.; Roy-Chowdhury, Sharmila; Lum, Sharon S.; Morgan, John W.; Kazanjian, Kevork.

In: American Surgeon, Vol. 76, No. 10, 10.2010, p. 1092-1095.

Research output: Contribution to journalArticle

Kuo, I, Wong, JH, Roy-Chowdhury, S, Lum, SS, Morgan, JW & Kazanjian, K 2010, 'The use of pelvic radiation in stage II rectal cancer: A population-based analysis', American Surgeon, vol. 76, no. 10, pp. 1092-1095.
Kuo I, Wong JH, Roy-Chowdhury S, Lum SS, Morgan JW, Kazanjian K. The use of pelvic radiation in stage II rectal cancer: A population-based analysis. American Surgeon. 2010 Oct;76(10):1092-1095.
Kuo, Isabella ; Wong, Jan H. ; Roy-Chowdhury, Sharmila ; Lum, Sharon S. ; Morgan, John W. ; Kazanjian, Kevork. / The use of pelvic radiation in stage II rectal cancer : A population-based analysis. In: American Surgeon. 2010 ; Vol. 76, No. 10. pp. 1092-1095.
@article{9baa4fd24ee340689db3fb38c0728583,
title = "The use of pelvic radiation in stage II rectal cancer: A population-based analysis",
abstract = "National Institutes of Health (NIH) guidelines recommend the use of pelvic radiation in T3N0 rectal cancer. We sought to determine the rate of compliance with NIH radiation guidelines for patients with T3N0 rectal cancer. We performed a retrospective cohort study of T3N0 rectal cancer diagnosed between January 1, 1994, and December 31, 2003, in Region 5 of the California Cancer Registry (R5 CCR). Three hundred twenty-nine patients with T3N0 rectal cancer were identified. The mean age of the study population was 68 years (range, 28 to 93 years). Only 54.1 per cent of patients with T3N0 cancer received pelvic radiation. There was no difference in gender (P = 0.13) or the number of nodes examined (P = 0.19) between patients who had treatment with pelvic radiation and those who did not. However, patients receiving radiation were significantly younger (mean 64 years with radiation therapy [XRT] vs 72 years without XRT, P <0.001) and significantly more likely to be treated with systemic chemotherapy (75{\%} with XRT vs 8.6{\%} without XRT, P <0.001). Significant numbers of patients with T3N0 rectal cancer are not receiving pelvic radiation in R5 CRR. NIH guidelines are not being translated into clinical practice. The reasons for this warrant continued investigation.",
author = "Isabella Kuo and Wong, {Jan H.} and Sharmila Roy-Chowdhury and Lum, {Sharon S.} and Morgan, {John W.} and Kevork Kazanjian",
year = "2010",
month = "10",
language = "English (US)",
volume = "76",
pages = "1092--1095",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "10",

}

TY - JOUR

T1 - The use of pelvic radiation in stage II rectal cancer

T2 - A population-based analysis

AU - Kuo, Isabella

AU - Wong, Jan H.

AU - Roy-Chowdhury, Sharmila

AU - Lum, Sharon S.

AU - Morgan, John W.

AU - Kazanjian, Kevork

PY - 2010/10

Y1 - 2010/10

N2 - National Institutes of Health (NIH) guidelines recommend the use of pelvic radiation in T3N0 rectal cancer. We sought to determine the rate of compliance with NIH radiation guidelines for patients with T3N0 rectal cancer. We performed a retrospective cohort study of T3N0 rectal cancer diagnosed between January 1, 1994, and December 31, 2003, in Region 5 of the California Cancer Registry (R5 CCR). Three hundred twenty-nine patients with T3N0 rectal cancer were identified. The mean age of the study population was 68 years (range, 28 to 93 years). Only 54.1 per cent of patients with T3N0 cancer received pelvic radiation. There was no difference in gender (P = 0.13) or the number of nodes examined (P = 0.19) between patients who had treatment with pelvic radiation and those who did not. However, patients receiving radiation were significantly younger (mean 64 years with radiation therapy [XRT] vs 72 years without XRT, P <0.001) and significantly more likely to be treated with systemic chemotherapy (75% with XRT vs 8.6% without XRT, P <0.001). Significant numbers of patients with T3N0 rectal cancer are not receiving pelvic radiation in R5 CRR. NIH guidelines are not being translated into clinical practice. The reasons for this warrant continued investigation.

AB - National Institutes of Health (NIH) guidelines recommend the use of pelvic radiation in T3N0 rectal cancer. We sought to determine the rate of compliance with NIH radiation guidelines for patients with T3N0 rectal cancer. We performed a retrospective cohort study of T3N0 rectal cancer diagnosed between January 1, 1994, and December 31, 2003, in Region 5 of the California Cancer Registry (R5 CCR). Three hundred twenty-nine patients with T3N0 rectal cancer were identified. The mean age of the study population was 68 years (range, 28 to 93 years). Only 54.1 per cent of patients with T3N0 cancer received pelvic radiation. There was no difference in gender (P = 0.13) or the number of nodes examined (P = 0.19) between patients who had treatment with pelvic radiation and those who did not. However, patients receiving radiation were significantly younger (mean 64 years with radiation therapy [XRT] vs 72 years without XRT, P <0.001) and significantly more likely to be treated with systemic chemotherapy (75% with XRT vs 8.6% without XRT, P <0.001). Significant numbers of patients with T3N0 rectal cancer are not receiving pelvic radiation in R5 CRR. NIH guidelines are not being translated into clinical practice. The reasons for this warrant continued investigation.

UR - http://www.scopus.com/inward/record.url?scp=78651356139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651356139&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 1092

EP - 1095

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 10

ER -